文献速递脑血管病神经重症与神经感染

阿尔伯塔卒中项目早期CT评分与血管内治疗对大血管闭塞性卒中患者疗效和安全性的关联:RESCUE-Japan LIMIT试验的二次分析

Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion: A Secondary Analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT).
PubMed 文献 · JAMA Neurol · 2022-01-01

本研究为RESCUE-Japan LIMIT随机临床试验的二次分析,纳入202例大缺血核心(ASPECTS 3-5)急性大血管闭塞卒中患者,比较血管内治疗联合药物治疗与单纯药物治疗。ASPECTS 4-5患者中血管内治疗与90天功能结局改善相关,而ASPECTS≤3患者中未观察到显著获益,且颅内出血风险显著增加。

要点

  • ASPECTS 4-5患者中,EVT组43.2% vs 无EVT组7.7%达到mRS 0-3(OR 9.12)。
  • ASPECTS≤3患者中,EVT组21.4% vs 无EVT组18.0%达到mRS 0-3(OR 1.24)。
  • ASPECTS≤3患者接受EVT时颅内出血风险显著增加(OR 4.14)。

核心结论

  • 在急性大血管闭塞性卒中且ASPECTS为4-5的患者中,血管内治疗与90天功能结局改善相关;在ASPECTS≤3的患者中未观察到该关联。

研究设计与样本

  • RESCUE-Japan LIMIT为开放标签随机临床试验,2018年11月至2021年12月在日本45家卒中中心开展。
  • 试验纳入大缺血区域(ASPECTS 3-5,主要由磁共振成像判定)且颈内动脉或大脑中动脉M1段闭塞的成人急性缺血性卒中患者。
  • 203例入组患者中1例撤回知情同意,202例纳入原试验及本二次分析;二次分析于2022年4月进行。
  • 患者随机分配至血管内治疗联合药物治疗组或单纯药物治疗组。

主要发现

  • 202例患者中106例(52%)ASPECTS≤3(平均[SD]年龄76.7[9.6]岁;女性54例[50.9%]),96例ASPECTS 4-5(平均[SD]年龄75.6[10.6]岁;女性36例[37.5%])。
  • ASPECTS≤3患者中,EVT组12例(21.4%)vs 无EVT组9例(18.0%)90天mRS 0-3(OR 1.24;95%CI 0.47-3.26)。
  • ASPECTS 4-5患者中,EVT组19例(43.2%)vs 无EVT组4例(7.7%)90天mRS 0-3(OR 9.12;95%CI 2.80-29.70;交互作用P=0.01)。
  • ASPECTS≤3患者中mRS全范围序贯移位未达统计学显著(共同OR 1.56;95%CI 0.79-3.10),ASPECTS 4-5患者中达统计学显著(共同OR 4.48;95%CI 2.07-9.71;交互作用P=0.046)。
  • ASPECTS≤3患者接受EVT时颅内出血风险显著增加(OR 4.14;95%CI 1.84-9.32),ASPECTS 4-5患者中增加未达统计学显著(OR 2.05;95%CI 0.89-4.73;交互作用P=0.24)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Endovascular therapy (EVT) has been found to reduce functional disability in patients with acute stroke due to large-vessel occlusion. However, the extent of the ischemic region, measured using Alberta Stroke Program Early Computed Tomography Scores, may limit the efficacy of EVT. OBJECTIVE: To compare the efficacy and safety of EVT according to ASPECTS 3 or less vs 4 to 5. DESIGN, SETTING, AND PARTICIPANTS: The Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT) was an open-label randomized clinical trial conducted from November 2018 to December 2021 at 45 stroke centers across Japan. The trial enrolled adult patients with acute ischemic stroke with a large ischemic region, defined as ASPECTS 3 to 5 primarily determined by magnetic resonance imaging, with occlusion site at the internal carotid artery or middle cerebral artery segment 1. Among 203 enrolled patients, 1 withdrew consent and 202 were included in the original trial and secondary analysis. This secondary analysis was conducted in April 2022. INTERVENTIONS: Patients were randomly assigned to EVT with medical therapy or medical therapy alone. MAIN OUTCOMES AND MEASURES: Modified Rankin Scale (mRS) score at 90 days and symptomatic and any intracranial hemorrhage within 48 hours. RESULTS: Among 202 patients, 106 (52%) had ASPECTS 3 or less (mean [SD] age, 76.7 [9.6] years; 54 female individuals [50.9%]) and 96 had ASPECTS 4 to 5 (mean [SD] age, 75.6 [10.6] years; 36 female individuals [37.5%]). Of patients with ASPECTS 3 or less, 12 (21.4%) in the EVT group and 9 (18.0%) in the no EVT group had an mRS score of 0 to 3 (odds ratio [OR], 1.24; 95% CI, 0.47-3.26). Of patients with ASPECTS 4 to 5, 19 patients (43.2%) in the EVT group and 4 (7.7%) in the no EVT group had an mRS score of 0 to 3 at 90 days (OR, 9.12; 95% CI, 2.80-29.70; interaction P = .01). The ordinal shift across the range of mRS scores toward a better outcome was not significant in those with ASPECTS or 3 or less (common OR, 1.56; 95% CI, 0.79-3.10) but was significant in those with ASPECTS 4 to 5 (common OR, 4.48; 95% CI, 2.07-9.71; interaction P = .046). The risk of intracranial hemorrhage was significantly increased in patients with ASPECTS 3 or less when EVT was conducted (OR, 4.14; 95% CI, 1.84-9.32) and nonsignificantly increased in those with ASPECTS 4 to 5 (OR, 2.05; 95% CI, 0.89-4.73; interaction P = .24). CONCLUSIONS AND RELEVANCE: In this study, EVT was associated with improved 90-day functional outcomes in patients with acute large vessel occlusive stroke and ASPECTS was 4 to 5 but not in those with ASPECTS 3 or less. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03702413.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Uchida K, Shindo S, Yoshimura S, et al. Association Between Alberta Stroke Program Early Computed Tomography Score and Efficacy and Safety Outcomes With Endovascular Therapy in Patients With Stroke From Large-Vessel Occlusion: A Secondary Analysis of the Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism-Japan Large Ischemic Core Trial (RESCUE-Japan LIMIT). JAMA Neurol. 2022. PMID: 36215044. doi:10.1001/jamaneurol.2022.3285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。